Esperion Therapeutis.Inc. buy F1Trader
Summary
This prediction ended on 02.02.21 with a price of €28.06. The price of Esperion Therapeutis.Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -17.45%. F1Trader has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | 4.053% | 4.053% | 59.925% | -91.518% |
iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by F1Trader for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren